Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Immobilized Lytic Enzymes Prevent Listeria Growth on Food-related Surfaces

By BiotechDaily International staff writers
Posted on 18 Apr 2013
A coating of stabilized bacteriophage lytic enzymes could prevent Listeria from surviving on equipment and packaging used in the food industry.

Listeria is a genus of bacteria, of which the most common species is Listeria monocytogenes, commonly found in soil, on unwashed vegetables, and in unpasteurized soft cheeses. These bacteria resist cold and the presence of salt and can cause food poisoning (listeriosis) with flu-like symptoms such as high fever and dizziness. While healthy individuals may not have any symptoms, those with compromised immune systems such as pregnant women, infants, and the elderly are especially at risk.

Investigators at Rensselaer Polytechnic Institute (Troy, NY, USA) previously developed a coating that could kill methicillin-resistant Staphylococcus aureus (MRSA) without antibiotics. In the present study, they observed that while a number of phage cell lytic enzymes against Listeria had been isolated, no attempt had been made to incorporate these enzymes onto surfaces.

The investigators described in the April 2, 2013, online edition of the journal Scientific Reports the development of three simple routes for the surface incorporation of the Listeria bacteriophage endolysin Ply500. These routes included covalent attachment onto [US] Food and Drugs Administration (FDA)-approved silica nanoparticles (SNPs), incorporation of SNP-Ply500 conjugates into a thin poly(hydroxyethyl methacrylate) film, and affinity binding to edible crosslinked starch nanoparticles via construction of a maltose binding protein fusion.

Testing of these coated surfaces revealed that these Ply500 formulations were effective in killing L. innocua (a reduced pathogenic surrogate) at challenges up to 100,000 colony-forming units per milliliter both in non-growth-sustaining buffer solution as well as under growth conditions on lettuce. This is a significantly higher concentration of bacteria than is normally found in contaminated food.

"In this study, we have identified a new strategy for selectively killing specific types of bacteria. Stable enzyme-based coatings or sprays could be used in food supply infrastructure—from picking equipment to packaging to preparation—to kill Listeria before anyone has a chance to get sick from it," said contributing author Dr. Ravi Kane, professor of chemical and biological engineering at Rensselaer Polytechnic Institute. "What is most exciting is that we can adapt this technology for all different kinds of harmful or deadly bacteria."

Related Links:
Rensselaer Polytechnic Institute



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.